Devicare has revamped the websites for their two medical solutions that are unique on the market (first-in-class): Tao-Control® for chronic anticoagulated patients and the Lit-Control® product line for urinary health.
Last news about Devicare
The Catalan Finance Institute (ICF), in collaboration with ACCIÓ (Agency for business competitiveness of the Generalitat of Catalonia), granted Devicare participation loan of 133,000 euros as part of the Corporate Entrepreneurship Programme in order to join...
The Association of Out-Patient Clinics and Entities of the Community of Madrid (ACESIMA) and Devicare have signed a strategic collaboration agreement to promote R&D&I and the use and training of innovative healthcare services and technologies intended for the in-home self-management of chronic patients in therapeutic fields such as the cardiovascular and urological fields, among others.
UIB, the Hospital de Manacor and Devicare launch a study to evaluate the effect of theobromine, the first inhibitor that prevents renal lithiasis
The Laboratory of Renal Lithiasis Research at the University of the Balearic Islands (UIB) will carry out a study among patients to evaluate the effects of theobromine, a substance that acts as an inhibitor of uric acid crystallisation in urine and that was patented as a dietary supplement by the UIB research team led by Dr. Fèlix Grases. The study will be carried out in collaboration with the Urology Service of the Hospital de Manacor,...
Devicare has joined the Associate Collaborators' Forum (FAC) of The Catalan Hospitals Union (La Unió), a body made up of more than 25 industrial and service companies that operate in the health, social and attention to dependency fields. Through this forum, La Unió aims to promote the relationship between the associate collaborators, such as Devicare, and the health and social centers of Catalonia in order to encourage partnerships for innovation in management and also strengthen the role of business lobbying in the sector.
Devicare has signed an agreement with the company Inmave to market the family of Lit-Control® products in Colombia for the domiciliary control of frequent urological pathologies. Colombia is the second American country and the fourth globally, after Spain, Mexico and France, to distribute this first-in-class method. The two companies have begun the regulation process with the Colombian National Institute for Medicine and Food Surveillance (INVIMA) with the support of ACCIÓ de Bogotá's office.
Devicare has signed a collaboration agreement with the Allegra Residential Complex in Sabadell, Barcelona in order to offer Lit-Control® and Tao-Control® to its residents. These two innovative services will allow users of the nursing home (161 beds), rental apartments (27 beds) and the day centre who suffer from long-term urological diseases, such as recurrent urinary tract infections, or who take oral anticoagulants, to self-monitor their health with the benefits that this entails.
Devicare se prepara para introducir en Francia la familia de productos Lit-Control® (dispositivo médico y suplementos alimenticios) y así potenciar el autocontrol domiciliario de patologías urológicas frecuentes a través del manejo y el control del pH urinario. Con este fin, la compañía acaba de incorporar al Dr. François Schutze como Country Manager. El Dr. François…
Devicare, a company specializing in innovative medical devices for chronic home care patients under Remote Patient Monitoring (RPM), has closed out a seed round of 3 million euros. This funding will be used to consolidate the launch of clinical studies of two of Devicare's main product lines on the Spanish market: Lit-Control® for prevention and self-management of recurring urinary diseases and Tao-Control® for self-management of patients who take oral anticoagulants (Sintrom®, Aldocumar®, etc.).
The National Innovation Company (ENISA) has granted Devicare a loan of EUR 270,000 in order to support its expansion plan. This amount is allocated from the ENISA Entrepreneurs line of credit, which finances innovative SMEs so that they can invest in and develop their projects. The maximum loan amount granted is EUR 300,000. This year the company expects to obtain sales of 1.1 million euros and introduce the Lit-Control® line on new international markets, as well as consolidate the Tao-Control® service in Spain. The Devicare staff currently consists of 20 professionals. This is not the first time Devicare has received support from ENISA.